Xindan Zhang
State Key Laboratory Of Biotherapy
Chengdu, 610041, China
Chengdu, 610041, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Structural basis of mpox virus A30/H2 subcomplex formation.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 05, 2026
Modification of a SARS-CoV-2 spike-RBD targeting nanobody for pH-dependent binding and its chromatographic engineering for purification of WT and variant S-RBDs with mild elution conditions.
Journal: International journal of biological macromolecules
Published: April 24, 2025
LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants.
LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants.
Journal: Cell proliferation
Published: February 11, 2025
Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants.
Journal: PLoS pathogens
Published: September 08, 2024
Structural and functional basis of low-affinity SAM/SAH-binding in the conserved MTase of the multi-segmented Alongshan virus distantly related to canonical unsegmented flaviviruses.
Journal: PLoS pathogens
Published: March 10, 2023
Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization.
Journal: PLoS pathogens
Published: March 10, 2023
An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry.
Journal: Emerging microbes & infections
Published: June 27, 2022
Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding.
Journal: Signal transduction and targeted therapy
Published: January 20, 2022
A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
Journal: Frontiers in immunology
Published: November 22, 2021
S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis.
Journal: Signal transduction and targeted therapy
Published: July 01, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026